Short Bowel Syndrome Market: Introduction

According to the report, the global short bowel syndrome market was valued at US$ 728.3 Mn
in 2020 and is projected to expand at a CAGR of 15.9% from 2021 to 2031. Incentives and R&D
grants for manufacturers of orphan drugs, rise in prevalence of SBS, and favorable
reimbursement scenario are anticipated to propel the global short bowel syndrome market.
Japan is likely to be a highly lucrative market for short bowel syndrome drugs
from 2021 to 2031. The market in the country is projected to expand at a high CAGR during the
forecast period.
Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?
flag=B&rep_id=13346
Increase in Demand for SBS Drugs Due to High Cost of Parenteral Nutrition to Drive Market
Most of the short bowel syndrome patients are on parenteral nutrition initially until the
patients’ intestine has adopted and hemostasis is being maintained. The cost of parenteral
nutrition varies from patient to patient, and ranges between US$ 150,000 and US$ 586,000 per
year. The high cost of parenteral nutrition increases demand for short bowel syndrome drugs,
which have shown the ability to reduce patient’s dependence on parenteral nutrition during the
clinical trials. For instance, apraglutide has the potential to enable patients to minimize the
burden from parenteral support by increasing intestinal absorption of fluids, calories, and
nutrients. Apraglutide has completed phase 2 studies and is currently being evaluated in a
pivotal phase 3 clinical trial. Based on preclinical and clinical data to date, apraglutide has the
potential to facilitate the treatment of SBS-IF by establishing less frequent dosing and
improving outcomes in a clinically meaningful fashion to address the needs of patients across
the anatomical spectrum that characterizes the disease.
Request a Sample of Short Bowel Syndrome Market:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346

Glucagon-like Peptide-2 (GLP-2) to Dominate Global Market

In terms of product, the global short bowel syndrome market has been classified into glucagon-
like peptide-2 (GLP-2), growth hormone, glutamine, and others. The glucagon-like peptide-2
segment dominated the global short bowel syndrome market in 2020, and the trend is
projected to continue during the forecast period.  The segment’s dominance can be attributed
to increase in sales of Gattex/Revestive in the U.S. and Europe. Additionally, it is the only
approved drug for the treatment of SBS across the globe.
Request for Analysis of COVID19 Impact on Short Bowel Syndrome Market -
https://www.transparencymarketresearch.com/sample/sample.php?
flag=covid19&rep_id=13346

Retail Pharmacies to be Highly Lucrative Distribution Channel

Based on distribution channel, the global short bowel syndrome market has been divided into
hospital pharmacies, retail pharmacies, and online sales. The retail pharmacies segment
dominated the global short bowel syndrome market, and the trend is anticipated to continue
during the forecast period. The segment is expected to dominate the global short bowel
syndrome market due to higher sales of drugs through retail pharmacies in developed countries
including the U.S., Europe, and Canada.

Buy now Short Bowel Syndrome Market Report -

https://www.transparencymarketresearch.com/checkout.php?rep_id=13346&ltype=S

Competition Landscape

Key players in the global short bowel syndrome market include Takeda Pharmaceutical
Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters
Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., and Pharmascience, Inc.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/need-for-efficient-drug-development-across-
various-sectors-to-bring-phenomenal-growth-prospects-for-biosimulation-market-between-
2020-and-2030-opines-tmr-301147587.html

https://www.prnewswire.co.uk/news-releases/single-use-cystoscope-market-to-reach-
valuation-of-us-150-mn-by-2031-growing-acceptance-of-patient-ready-instruments-in-urology-
to-bolster-demand-tmr-study-818277477.html

https://www.prnewswire.com/news-releases/extensive-research-and-development-efforts-to-
underscore-growth-in-photodynamic-therapy-market-from-2019-to-2027-tmr-301150981.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global

business information reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for thousands of decision makers. We have an
experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources
and various tools and techniques to gather, and analyze information. Our business offerings
represent the latest and the most reliable information indispensable for businesses to sustain a
competitive edge.

Each TMR Syndicated Research report covers a different sector — such as pharmaceuticals,
chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and
technology. These reports provide in-depth analysis and deep segmentation to possible micro
levels. With wider scope and stratified research methodology, our syndicated reports thrive to
provide clients to serve their overall research requirement.

Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/